Press release
Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies
Curious about the latest updates in the Atopic Dermatitis Pipeline? Click here to explore the therapies and trials making headlines @ Atopic Dermatitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Atopic Dermatitis Pipeline Report
* On 07 October 2025, Incyte Corporation announced a study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to
* On 06 October 2025, Aclaris Therapeutics Inc . announced a study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
* On October 6, 2025, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a leader in immuno-dermatology, announced FDA approval of the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream 0.05% for children aged 2 to 5 with mild to moderate atopic dermatitis. This once-daily topical therapy offers fast, effective clearance of the condition anywhere on the body, presenting a steroid-free alternative for parents, caregivers, and clinicians that can be safely used for extended periods.
* DelveInsight's Atopic Dermatitis Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Atopic Dermatitis treatment.
* The leading Atopic Dermatitis Companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
* Promising Atopic Dermatitis Therapies such as Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL , and others.
Want to know which companies are leading innovation in Atopic Dermatitis? Dive into the full pipeline insights @ Atopic Dermatitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Atopic Dermatitis Pipeline Report also highlights the unmet needs with respect to the Atopic Dermatitis.
Atopic Dermatitis Overview
Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means 'skin' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.
Atopic Dermatitis Emerging Drugs Profile
* ICP-332: Innocare Pharma
ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.
* APG777: Apogee Therapeutics
APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.
* Barzolvolimab: Celldex Therapeutics
Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.
* ATI-2138: Aclaris Therapeutics
ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.
* STAR-0310: Astria Therapeutics
STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.
If you're tracking ongoing Atopic Dermatitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Atopic Dermatitis Treatment Drugs [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Atopic Dermatitis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
* Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
Atopic Dermatitis Companies
Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Atopic Dermatitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Atopic Dermatitis Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Atopic Dermatitis Pipeline Report covers it all - check it out now @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atopic Dermatitis Pipeline Report
* Coverage- Global
* Atopic Dermatitis Companies- Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
* Atopic Dermatitis Therapies- Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL , and others.
* Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Atopic Dermatitis Treatment landscape in this detailed analysis @ Atopic Dermatitis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Atopic Dermatitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atopic Dermatitis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ICP-332: Innocare Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* APG777: Apogee Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* STAR-0310: Astria Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Atopic Dermatitis Key Companies
* Atopic Dermatitis Key Products
* Atopic Dermatitis- Unmet Needs
* Atopic Dermatitis- Market Drivers and Barriers
* Atopic Dermatitis- Future Perspectives and Conclusion
* Atopic Dermatitis Analyst Views
* Atopic Dermatitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-pipeline-outlook-report-2025-insight-into-emerging-drugs-treatment-options-clinical-trials-and-company-strategies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies here
News-ID: 4214601 • Views: …
More Releases from ABNewswire
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure.
Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is…
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business.
KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus.
Each collection features 30 professionally produced instrumental tracks, available in both WAV…
Book Now the Emerging Gospel Artist "Jacqueline L. Jenkins" debuts new single "A …
BIOGRAPHY
Jacqueline L. Jenkins is an emerging gospel artist celebrated for her heartfelt lyrics and soulful vocals that blend traditional gospel spirit with contemporary rhythms. She first gained recognition with her debut single, "Thank You," which resonated deeply with listeners through its message of gratitude and faith. In 2024, Jacqueline released the Thank You - EP, featuring standout tracks such as "Going Home," a poignant tribute to her late mother, and…
Why More People Are Choosing Mobile Hair and Beauty Services Through DashStylist …
People are seeking a means of making their lives easier in the hectic world we all live in. Mobile beauty and hair services are one of the trends that are on the rise. These services help save time and efforts as the salon experience has been delivered to the home of the customer. Customers do not have to drive to a salon, wait until their turn comes and then drive…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
